An honorary Doctor of science (D.Sc.) with a master's degree in chemistry, Dr. Gupta, in his early career was an Associate Professor at Birla Institute of Science and Technology, Pilani, Rajasthan. Since 1968, when he founded the company, Dr Gupta has steered Lupin towards the forefront of India pharmaceuticals.

In recent years, he has spearheaded the restructuring of Lupin's operations, and the research and innovation programs in new drug research and novel drug delivery systems

Dr Kamal K Sharma is a graduate in chemical engineering from the Indian institute of Technology (IIT), Kanpur, with a post-graduate diploma in industrial management from Jamnalal Bajaj Institute of management Studies, Mumbai, and a Ph.D in economics from IIT, Mumbai. He has also completed an advanced management program from Harvard Business School, Boston.

In a career spanning more than three decades, Dr. Sharma has held a range of senior management positions managing projects, corporate development and general management in the pharmaceuticals and chemicals industries.

A graduate in arts, Mrs. Gupta is one of the promoters of the company with a wide business experience.

A graduate in pharmacy from the University of Mumbai and MBA from J L Kellog Graduate School of Management, Mrs. Vinita Gupta has been instrumental in Lupin's forays into the Advanced Markets and heads the Advanced Market business of the company in the markets of USA and Europe. Under her leadership, Lupin has emerged as a global generic player, especially in the US market in addition to becoming a strong player in the pediatric branded market. She is also a Director on the Board of Lupin Ltd.

Mr Nilesh Gupta is Group President and Executive Director to the Board of Lupin. He is a Chemical Engineer from the University Department of Chemical Technology (UDCT), Mumbai, and a graduate with honors from the Wharton School, University of Pennsylvania, USA, where he specialized in healthcare, strategic management and finance.

All Research comprising of Drug Discovery, Process Research, Formulation Research and the IP Group reports in to him. He is also in charge of Lupin's Supply Chain comprising of all API and Finished Product manufacturing locations in addition to heading the Regulatory, Quality and Projects functions.

Dr. Vijay Kelkar has held senior positions in the Government of India and was Chairman/Member of several high-powered Committees set-up by various ministries. He has also served roles in the Finance Ministry, the latest being Chairman of the 13th Finance Commission, and is a very well known face in the global advisory and Lecture circuit.

Having delivered lectures at various Universities in India and globally. He was the Finance Secretary, Government of India from 1998 -1999, Executive Director for India, Sri Lanka, Bangladesh and Bhutan at the IMF, Washington from August 1999 to August 2002 and Advisor to

Minister of Finance, Government of India in the rank of a Minister of State from August 2002 to September 2004. He has authored many books, publications and journals on micro and macroeconomics, functioning of Indian public sector undertakings, their problems and emerging challenges and trade policies & reforms in India. Dr. Kelkar was an Independent Director on the Board of Lupin during the period from October 19, 2005 till December 31, 2007. Upon his appointment by the President of India, as Chairman of the 13th Finance Commission, Dr. Kelkar relinquished his directorship w.e.f. December 31, 2007.

With more than 30 years of experience in the Biotechnology and Pharmaceutical Industries globally, Mr. Richard Zahn is a well recognized thought leader and strategist in healthcare research and development, professional and consumer marketing, corporate strategy, sales force management, managed care, State and Federal relations, and human resources.

Prior to this, Mr. Zahn was the President of Schering Laboratories, Director, Schering Corporation and Corporate Vice President of Schering-Plough Corporation. As President of Schering, he directed the

Corporation's primary business unit through the most dynamic growth period in its history, transforming it from a US $1.5 billion organization to a US $ 6 billion major company. Under his stewardship, Schering Laboratories created and developed important prescription therapeutic markets. His leadership transformed Schering-Plough Healthcare Products (OTC company for Schering-Plough) into a major force. Mr. Zahn spent 20 years rising through the ranks with increasing responsibility at Johnson & Johnson before being recruited to the Senior Management levels at Schering-Plough.

Mr. R. A. Shah is an eminent Solicitor specialising in a broad spectrum of Corporate Laws. He is a senior partner of Crawford Bayley & Company, a leading firm of Solicitors and Advocates in Mumbai.

He is on the boards of several reputed companies. Mr. Shah is a member of the Managing Committee of Bombay Chamber of Commerce and Indo German Chamber of Commerce. He is President of Society of Indian Law Firms (Western Region).

A Ph.D.in Economics from University of Bombay, with a Certificate in Financial Management from JBIMS, Mr. K U Mada is an eminent economist and development banker. He has served in key positions with IDBI as its Executive Director for over three years.

He was Chairman/Member of a number of committees constituted by IDBI and other financial institutions and the Government of India.

Mr. Dileep C. Choksi, a leading Chartered Accountant by profession, has over 35 years of experience having qualified as a lawyer and a Cost Accountant. His areas of specialisation include tax planning and structuring for domestic and international clients, including expatriates, finalising collaborations and joint ventures, executive advisory and decision support, corporate restructuring with a focus on startup, turnaround and change management strategies and analysing tax impact of various instruments. He advises some of India’s largest business houses on various strategic matters and multinational clients on cross border structuring.